Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as individualized neoantigen and checkpoint adaptive immune modulation therapy; and rare disease products, including propionic and methylmalonic acidemia, glycogen storage disease type 1a, ornithine transcarbamylase deficiency, phenylketonuria, crigler-najjar syndrome type 1, and cystic fibrosis. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Generation Bio Co.; immatics N.V.; Life Edit Therapeutics; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Moderna, Inc.

The pharma company’s share price soared on news of a cancer drug breakthrough. 


Moderna Stock (MRNA) Was the Best Performer in August

Moderna ( ($MRNA) ) has risen by 125.15%. Read on to learn why. Moderna has delivered one of the most dramatic moves in biotech this week, with its...

Moderna’s Shock Rally Redraws the Biotech Playbook

Analysts are intrested in these 5 stocks: ( ($MRNA) ), ( ($ADI) ), ( ($MRK) ), ( ($EPR) ) and ( ($TJX) ). Here is a breakdown of their recent


Moderna, ADI, Merck, EPR, TJX: Trending With Analysts

Shares in Moderna ($MRNA) climbed by 13% to $151 per share on Friday afternoon. This came even after JPMorgan’s five-star analyst Jessica Fye repea...

Moderna Stock (MRNA) Jumps 13% Despite JPMorgan’s Sell Rating

Moderna ($MRNA) announced an update on their ongoing clinical study. ModernaTX, Inc. (MRNA) is running a Phase 3 study called “A Phase 3 Study to E...

Moderna’s RSV Vaccine Trial Reaches Completion, Setting Up a Key Catalyst for MRNA

Moderna (NASDAQ:MRNA) stock is giving back part of Wednesday’s huge gain, falling about 18% on Thursday as Wall Street’s response to the latest can...

Why Moderna Stock Is Plunging Today — and What Wall Street Sees Ahead

Jefferies analyst Andrew Tsai reiterated a Hold rating on Moderna today and set a price target of $60.00. According to TipRanks, Tsai is a 5-star a...

Jefferies Reaffirms Their Hold Rating on Moderna (MRNA)

The shares had been heavily shorted on Wall Street. 


Short Sellers Lose $4.8 Billion as Moderna Stock (MRNA) Soars 150%

For Moderna (NASDAQ:MRNA) investors, Wednesday feels a little like the good old COVID-19 days, with shares soaring over 140% in one day. The jump c...

JPMorgan Weighs In on Moderna Stock Amid 140%-Plus Jump (And It Ain’t Pretty)

Tempus AI ($TEM) surged nearly 24% on Wednesday after a major Phase 3 cancer vaccine update from Merck ($MRK) and Moderna ($MRNA). The news instant...

Tempus AI Stock (TEM) Is Surging 24% on Wednesday – Here’s Why

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Merck & Company (MRK), Moderna (MRNA) and Akari Th...

Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK), Moderna (MRNA) and Akari Therapeutics (AKTX)

Pfizer stock was up 3.74% thanks to a clinical trial update from Merck and Moderna that showed the potential of an MRNA vaccine as a cancer treatme...

Pfizer (PFE) Stock Rallies 4% Thanks to Merck (MRK) and Moderna (MRNA)’s Cancer Trial Update

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Amylyx Pharmaceuticals Inc (AMLX), Moderna (MRNA) ...

Analysts Conflicted on These Healthcare Names: Amylyx Pharmaceuticals Inc (AMLX), Moderna (MRNA) and Merck & Company (MRK)

Moderna ($MRNA) announced an update on their ongoing clinical study. ModernaTX, Inc. has launched a new early-stage trial called “A Phase 1, Random...

Moderna Expands Respiratory Vaccine Pipeline With New RSV/hMPV Trial in Older Adults

Moderna stock ($MRNA) fell 1.5% to $55.39 on Thursday despite getting big news from health regulators. The Food and Drug Administration approved Mo...

Moderna Stock Slips Despite FDA Approval for New Flu Shot mFlusiva

Moderna ($MRNA) announced an update on their ongoing clinical study. Moderna (MRNA) has halted a key early study of mRNA-1468, its experimental shi...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	MRNA	$145.55	-2.23%	12.37M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	MRNA	$145.55	-2.2%	12.37M
3
4
5
6

MRNA

Get Moderna, Inc. Data in Excel

Get Moderna, Inc. Data in Excel